Canada· CA-DIN-02026961
KAYEXALATE
A polystyrene sulfonate product containing sodium polystyrene sulfonate, registered in Canada by SANOFI-AVENTIS CANADA INC. The same ATC class is registered in 11 of our 19 countries.
Checked against Health Canada Drug Product Database (Canada) on
Informational only — not a medical device.
Where it is registered
Polystyrene sulfonate is registered in 11 of 19 countries.
Countries holding a registration under ATC V03AE01 (polystyrene sulfonate), each read from that country’s own register.
- This record: Canada, from Health Canada Drug Product Database (Canada)
- 7 of them publish a price we can compare per daily dose
Polystyrene sulfonate · ATC V03AE01
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
Price per daily dose
What a daily dose of polystyrene sulfonate costs, country by country.
Normalised to the WHO defined daily dose (45 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Polystyrene sulfonate · price per daily dose (45 g)
USD · FX 28 Sept 2026
- CZ Czechia$0.0074
The record
At a glance
Health Canada Drug Product Database (Canada)- Active substance
- SODIUM POLYSTYRENE SULFONATE
- Manufacturer
- SANOFI-AVENTIS CANADA INC
- Country
- Canada (CA)
- ATC code
- V03AE01
- ATC class
- Polystyrene sulfonate
- Defined daily dose
- 45 g, O
- Reimbursed
- Not published by this register
- Source register
- Health Canada Drug Product Database (Canada)
- Last checked
- October 1, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Polystyrene sulfonate in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesKionexANI Pharmaceuticals, Inc.
- GermanyAnti-Kalium NaMedice Arzneimittel Pütter Gmbh & Co. Kg
- Japanポリスチレンスルホン酸ナトリウム鳥居薬品
- FrancePOLYSTYRENE SULFONATE DE SODIUM SUBSTIPHARM 454 g, poudre pour suspension orale et rectaleSUBSTIPHARM
- United KingdomResonium A powderSanofi
- BelgiumKayexalate Sodium 14.99 gSanofi Belgium
- FinlandResoniumSanofi Oy
Authorised across Europe · EMA
The same active substance is authorised in 15 EEA countries. Names it is sold under:
- Austria · Resonium A
- Belgium · Kayexalate Sodium
- Cyprus · Resinsodio
- Germany · Anti-Kalium Na, Elutit®-Natrium-As
- Spain · Resinsodio
- Finland · Resonium
- France · Kayexalate, Lykasty
- United Kingdom (Northern Ireland) · Resonium A
- Hungary · Resonium
- Italy · Kayexalate
- Luxembourg · Kayexalate Sodium
- Netherlands · Natriumpolystyreensulfonaat Focus, Resonium A
- Poland · Resonium A
- Portugal · Resonium
- Sweden · Resonium
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7e37ccaa-8d07-4dbe-ac92-5a1645ab891c GET /v1/drugs/7e37ccaa-8d07-4dbe-ac92-5a1645ab891c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"din": "02026961",
"form": "POWDER FOR SUSPENSION",
"class": "Human",
"routes": [
"ORAL",
"RECTAL"
],
"source": "health_canada_dpd",
"status": "MARKETED",
"atc_raw": "V03AE01",
"schedule": [
"Prescription"
],
"drug_code": "17752",
"strengths": [
"1 G"
],
"ahfs_class": null,
"substances": [
"SODIUM POLYSTYRENE SULFONATE"
],
"product_categorization": null
}See everything about polystyrene sulfonate.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.